MMSI Merit Medical Systems Inc.

Merit Medical Systems to Announce Third Quarter 2025 Results on October 30, 2025

Merit Medical Systems to Announce Third Quarter 2025 Results on October 30, 2025

SOUTH JORDAN, Utah, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2025, after the close of the stock market on Thursday, October 30, 2025. Merit plans to hold its investor conference call on the same day (Thursday, October 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific).

To access the conference call, please pre-register using the following . Registrants will receive confirmation with dial-in details.

A live webcast and slide deck can be accessed using this . A link to both register for the conference call and view the webcast will be made available at

ABOUT MERIT

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,400 people worldwide.

Contacts: 
PR/Media Inquiries:Investor Inquiries:
Sarah ComstockMike Piccinino, CFA, IRC
Merit MedicalICR Healthcare





EN
03/10/2025

Underlying

MMSIMerit Medical Systems Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

 PRESS RELEASE
Free
MMSI Merit Medical S...

Merit Medical Signs Asset Purchase Agreement with PENTAX Medical to Ac...

Merit Medical Signs Asset Purchase Agreement with PENTAX Medical to Acquire C2 CryoBalloon Technology Asset acquisition would expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders. Asset acquisition is projected to add approximately $6 million to $8 million of revenue in 2026 in a key gastroenterology market that leverages Merit’s existing commercial footprint.   SOUTH JORDAN, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare tech...

October 15, 2025 1 EN
 PRESS RELEASE
Free
MMSI Merit Medical S...

Merit Medical Systems to Announce Third Quarter 2025 Results on Octobe...

Merit Medical Systems to Announce Third Quarter 2025 Results on October 30, 2025 SOUTH JORDAN, Utah, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2025, after the close of the stock market on Thursday, October 30, 2025. Merit plans to hold its investor conference call on the same day (Thursday, October 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). ...

October 3, 2025 1 EN
 PRESS RELEASE
Free
MMSI Merit Medical S...

Merit Medical Announces SCOUT Milestone: 750,000 Patients Treated with...

Merit Medical Announces SCOUT Milestone: 750,000 Patients Treated with Wire-Free Technology SCOUT Radar Localization use grows, supporting more successful surgeries and improved patient care SOUTH JORDAN, Utah, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced a significant milestone for breast cancer treatment: SCOUT® Radar Localization use has reached 750,000 patients worldwide.1 This global achievement coincides with Breast Cancer Awareness Month, a time dedicated to educating the public about the ...

October 1, 2025 1 EN
 PRESS RELEASE
Free
MMSI Merit Medical S...

Merit Medical Embosphere Microspheres Achieve CE Mark for Genicular Ar...

Merit Medical Embosphere Microspheres Achieve CE Mark for Genicular Artery Embolisation to Treat Knee Osteoarthritis Expanded indication provides patients with knee osteoarthritis the benefits of Embosphere’s consistent, predictable, and effective clinical results. SOUTH JORDAN, Utah, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that Embosphere® Microspheres are now indicated in the European Union for use in genicular artery embolisation (GAE) to treat patients with knee osteoarthritis (OA). The...

September 12, 2025 1 EN
 PRESS RELEASE
Free
MMSI Merit Medical S...

First Patient Enrolled in Merit Medical’s WRAPSODY (WRAP) North Americ...

First Patient Enrolled in Merit Medical’s WRAPSODY (WRAP) North America Registry The WRAP North America registry is a prospective, multicenter study designed to collect real-world safety and effectiveness data on the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE).The first WRAP North America patient was enrolled at Bluff City Vascular, an interventional nephrology and vascular access center in Memphis, TN. SOUTH JORDAN, Utah, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today the successful enroll...

August 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch